Canalblog Tous les blogs Top blogs Beauté, Santé & Remise en forme Tous les blogs Beauté, Santé & Remise en forme
Suivre ce blog Administration + Créer mon blog
MENU
Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
Publicité
formulation
9 septembre 2015

NEUROPTIS BIOTECH TO SELL ML7 FOR R&D ACTIVITIES

 NEUROPTIS BIOTECH TO SELL ML7 FOR R&D ACTIVITIES
NEUROPTIS IS THE OWNER OF PATENTS ON THE SYNTHESIS OF PURIFIED AND STABLE ML7 ACCORDING TO THE REQUIREMENTS OF EMEA AND FDA WITHOUT ANY DEGRADATION PRODUCT NEUROPTIS HAS ALSO DEVELOPED METHODS OF DOSAGE OF ML7 (HPLC) IN DIFFERENT BIOLOGICAL LIQUIDS NEUROPTIS...
Publicité
26 juin 2015

Innovative formula prevents risks, painful treatments in people with secondary blindness

Innovative formula prevents risks, painful treatments in people with secondary blindness
Innovative formula prevents risks, painful treatments in people with secondary blindness Innovative formula prevents risks, painful treatments in people with secondary blindness The Mexican company "Medical and Surgical Center for Retina" created a way...
17 avril 2015

Liens professionnels avec Twitter

Liens professionnels avec Twitter
Quelques liens Twitter concernant les sociétés/personnes de la famille: antoine le galloudec (@APOTCARE) | Twitter The latest Tweets from antoine le galloudec (@APOTCARE). Founder of APOT.CARE High end dermocosmetic skincare line. PARIS http://twitter.com...
25 février 2015

LIGHT DEGRADATION OF ML7 FORMULATIONS BY OCTALIA TECHNOLOGIES CRO: CONCLUSION

LIGHT DEGRADATION OF ML7 FORMULATIONS BY OCTALIA TECHNOLOGIES CRO: CONCLUSION
Octalia Technologies - Vallauris, Alpes Maritimes, Côte d'azur, 06 Octalia Technologies is a fully independent drug delivery company specialized in the field of ophthalmology. Formulation, pharmaceutical drug development and applied research that integrate...
5 février 2015

ML7 FORMULATION FOR DRY EYE THERAPY

ML7 FORMULATION FOR DRY EYE THERAPY
LINK: OCTALIA_STABILITE_2013_115 ML7 FORMULATION FOR DRY EYE THERAPY STEP B – FORMULATION INVESTIGATIONS NEUROPTIS Issued date: February 07th, 2014 TABLE OF CONTENTS 1. Introduction ...........................................................................................................................
Publicité
31 janvier 2015

Note de synthèse sur les études réalisées par Iris Pharma

Note de synthèse sur les études réalisées par Iris Pharma
Lien: Note_de_synth_se_sur_les__tudes_r_alis_es_par_IrisPharma Note de synthèse sur les études réalisées par Iris Pharma Etude n°1 : Test de tolérance locale 1/ But de l’étude Evaluation de l’effet de 3 concentrations de ML7 (0,1%, 0,03% et 0,01%) chez...
8 janvier 2015

Study IRIS Pharma: evaluation of effectiveness of eye drop ML7 formulation in a rat modele of scopolamine-induced dry eye

Study IRIS Pharma: evaluation of effectiveness of eye drop ML7 formulation in a rat modele of scopolamine-induced dry eye
COMPTE RENDU DE L'ÉTUDE D'EFFICACITÉ 1. Summary Purpose: The aim of the study was to evaluate the therapeutic potential of topical applied ML7 formulation in a rat model of scopolamine-induced dry eye. Method: Dry eye symptoms were induced in albino Lewis...
Publicité
Publicité
Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
Newsletter
Publicité
Visiteurs
Depuis la création 33 495
Publicité